News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

Opinion|Videos|December 2, 2024

VMS Treatment Guidelines

Author(s)Mary Jane Minkin, MD, Lisa Larkin, MD, FACP, MSCP, IF

Panelists discuss key considerations for women taking hormonal therapy, emphasizing the importance of individualized treatment plans and shared decision-making to evaluate the risk-benefit profile of therapy.

Episodes in this series

EP. 1 Overview of KNDy neurons

EP. 1 Overview of KNDy neurons

EP. 2 VMS Symptoms and Neurokinin Receptor Antagonists

EP. 2 VMS Symptoms and Neurokinin Receptor Antagonists

EP. 3 Neurokinin and Estrogen Balance in Menopausal Hot Flashes for Primary Care

EP. 3 Neurokinin and Estrogen Balance in Menopausal Hot Flashes for Primary Care

EP. 4 Fezolinetant Guidelines and Emerging Data on Menopause and Liver Health

EP. 4 Fezolinetant Guidelines and Emerging Data on Menopause and Liver Health

EP. 5 Molecular Comparison and Safety Profiles of Fezolinetant and Elinzanetant

EP. 5 Molecular Comparison and Safety Profiles of Fezolinetant and Elinzanetant

EP. 6 Malignancy Risks of Neurokinin Receptor Antagonists

EP. 6 Malignancy Risks of Neurokinin Receptor Antagonists

EP. 7 Guidance for PCPs: Streamlining Menopause Care

EP. 7 Guidance for PCPs: Streamlining Menopause Care

EP. 8 Nonestrogen Treatments for Menopause

EP. 8 Nonestrogen Treatments for Menopause

EP. 9 VMS Treatment Guidelines

EP. 9 VMS Treatment Guidelines

Individualized therapy with shared decision-making is essential when evaluating the risk-benefit profile of hormonal therapy. What are some key considerations for a woman taking hormonal therapy?

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content

2 experts in this video

Clinicians’ Perspectives on Switching Contraceptives and Discussing Low-Dose Estrogen Combined Hormonal Contraceptives With Patients

ByAnita Nelson, MD ,Kathleen Morrell, MD, MPH

September 5th 2025

2 experts in this video

Managing Breakthrough Bleeding When Using Low-Dose Estrogen Combined Hormonal Contraceptives

ByAnita Nelson, MD ,Kathleen Morrell, MD, MPH

September 5th 2025

2 experts in this video

Decreased Hormone-Free Intervals and Amenorrhea With Low-Dose Estrogen Combined Hormonal Contraceptives

ByAnita Nelson, MD ,Kathleen Morrell, MD, MPH

August 28th 2025

2 experts in this video

Managing Misconceptions and Adverse Effects with Low-Dose Estrogen Combined Hormonal Contraceptives

ByAnita Nelson, MD ,Kathleen Morrell, MD, MPH

August 28th 2025

2 experts in this video

Other Low-Dose Estrogen Combined Hormonal Contraceptive Formulations

ByAnita Nelson, MD ,Kathleen Morrell, MD, MPH

August 21st 2025

Latest CME

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Trending on Contemporary OB/GYN

Contemporary OB/GYN’s top expert interviews from July 2026

FDA approves norelgestromin and ethinyl estradiol transdermal patch for contraception

New fertility tool to help determine chances of successful IVF launches

Joy Baker, MD, talks zuranolone's onset for postpartum depression

Bacterial vaginosis independently associated with increased STI co-infection